Web-based genetic counseling for cancer testing
A Randomized Hybrid Type I Effectiveness-Implementation Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NA · Abramson Cancer Center at Penn Medicine · NCT05427240
This study tests if online genetic counseling for cancer testing can help people understand their options just as well as in-person visits while making it easier for them to get the support they need.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Abramson Cancer Center at Penn Medicine (other) |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05427240 on ClinicalTrials.gov |
What this trial studies
This randomized non-inferiority study evaluates a web-based eHealth intervention as an alternative to traditional in-person genetic counseling for cancer genetic testing. The study aims to assess whether this self-directed approach can maintain or improve patient outcomes, including understanding and emotional responses, while increasing access to genetic testing. Participants will be randomly assigned to receive either the standard two-visit counseling model or the web-based intervention. The goal is to enhance the uptake of genetic services among individuals facing barriers to traditional counseling.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who meet the criteria for germline genetic testing and have not previously undergone such testing.
Not a fit: Patients with communication difficulties or uncontrolled psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase access to genetic testing for cancer, leading to earlier detection and better management of hereditary cancer risks.
How similar studies have performed: Other studies have shown promise in using digital health interventions for genetic counseling, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Speak and understand English * Male or Female * No prior germline genetic testing * Meet current National Comprehensive Cancer Network (NCCN) guidelines for germline genetic testing Exclusion Criteria: -Communication difficulties such as: * Uncorrected or uncompensated hearing and/or vision impairment * Uncorrected or uncompensated speech defects * Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Where this trial is running
Philadelphia, Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Angela R Bradbury, MD — University of Pennsylvania
- Study coordinator: Angela R Bradbury, MD
- Email: Angela.Bradbury@pennmedicine.upenn.edu
- Phone: 215 615 3341
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer